Platinum Articles

Articles

  • [DNA damage repair: An emerging strategy in metastatic prostate cancer].

    Genetic instability is one part of the oncogenic process. Gene mutations involved in DNA repair mechanisms can promote this genetic instability and participate in oncogenesis and metastatic progression.

    Published October 16, 2018
  • Antitumour activity of platinum compounds in advanced prostate cancer - a systematic literature review.

    BACKGROUND - For men with advanced castration-resistant prostate cancer (CRPC), several treatment options are available, including androgen receptor (AR) pathway inhibitors (abiraterone acetate, enzalutamide), taxanes (docetaxel, cabazitaxel) and a radionuclide (radium-223).

    Published April 11, 2016
  • Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

    Understanding the molecular underpinnings of sensitivity to specific therapies will advance the goal of precision medicine in prostate cancer (PCa). We identified three patients with metastatic castration-resistant PCa (mCRPC) who achieved an exceptional response to platinum chemotherapy (not first-line treatment for PCa), despite disease progression on prior standard therapies.

    Published October 14, 2016
  • Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer.

    Baseline sarcopenia or severe lean muscle deficiency is independently associated with increased mortality after cystectomy for muscle-invasive urothelial carcinoma of the bladder (MIUC). The impact of chemotherapy on muscle mass in MIUC patients remains undefined.

    Published November 15, 2018
  • Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome.

    Cisplatin-based chemotherapy (CBCT) is part of standard treatment of several cancers. In testicular cancer (TC) survivors, an increased risk of developing metabolic syndrome (MetS) is observed. In this epigenome-wide association study, we investigated if CBCT relates to epigenetic changes (DNA methylation) and if epigenetic changes render individuals susceptible for developing MetS later in life.

    Published December 12, 2019
  • Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.

    BACKGROUND/AIM - Platinum (Pt)-based neoadjuvant chemotherapy (NAC) is the standard-of-care for muscle-invasive bladder cancer (MIBC). However, the survival benefit with NAC is driven by patients with pathological response at cystectomy.

    Published February 9, 2016
  • Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.

    Carboplatin and paclitaxel (CP) had shown moderate efficacy in treating castration-resistant prostate cancer (CRPC) before standard first-line docetaxel chemotherapy became available. Currently, for patients with homology-directed repair gene defects as well as for unselected patients, platinum chemotherapy is administered after all standard treatments have been ineffective.

    Published July 24, 2019
  • Emerging first line treatment options for bladder cancer: A review of phase II and III therapies in the pipeline.

    The treatment of urothelial carcinoma (UC) had remained unchanged for several years until the recent FDA approval of immune checkpoint inhibitors (CPIs) in the salvage setting. Novel dual CPI-CPI and CPI-chemotherapy combinations are now being investigated aggressively as first line therapy for metastatic disease.

    Published December 14, 2017
  • Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.

    Alterations in fibroblast growth factor receptor 3 (FGFR3) occur in ∼15% of muscle-invasive bladder cancers (MIBCs) and metastatic urothelial carcinomas (mUCs).

    To determine the association between FGFR3 status and response to platinum-based chemotherapy in patients with MIBC or mUC.

    Published August 10, 2020
  • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

    Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases.

    Published October 24, 2018
  • Long-term Exposure to Circulating Platinum is Associated with Late Effects of Treatment in Testicular Cancer Survivors.

    The success of cisplatin-based chemotherapy for testicular cancer comes at the price of long-term and late effects related to healthy tissue damage. We assessed and modelled serum platinum (Pt) decay after chemotherapy and determined relationships between long-term circulating Pt levels and known late effects.

    Published September 18, 2015
  • Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systemic Review and Two-Step Meta-Analysis.

    BACKGROUND - Platinum-based neoadjuvant chemotherapy has been shown to improve survival outcomes in muscle-invasive bladder cancer patients. We performed a systemic review and meta-analysis to provide updated results of previous findings.

    Published April 12, 2016
  • Platinum exposure and cause-specific mortality among patients with testicular cancer.

    Although testicular cancer (TC) treatment has been associated with severe late morbidities, including second malignant neoplasms (SMNs) and ischemic heart disease (IHD), cause-specific excess mortality has been rarely studied among patients treated in the platinum era.

    Published December 26, 2019
  • Risk of Vascular Toxicity with Platinum-based Chemotherapy in Elderly Patients with Bladder Cancer.

    Platinum-based chemotherapy is widely used for bladder cancer, but is associated with vascular toxicity, especially thromboembolism. We evaluated short-term (

    We identified Medicare beneficiaries age 66-94 years diagnosed with stage II-III bladder cancer from 1998-2007 in the Surveillance, Epidemiology and End Results-Medicare database. We measured the association between platinum-based chemotherapy and vascular events (thromboembolic and non-thromboembolic) using Cox proportional hazard regression models.

    The sample included 5,057 patients, 21. 3% of whom received platinum-based chemotherapy. Patients receiving platinum-based chemotherapy were more likely to be younger and male with less comorbidity than patients not receiving any chemotherapy. During the first year after diagnosis, patients who received platinum-based chemotherapy had higher risk of thromboembolic event (19. 8% vs. 11. 6%, AHR: 1. 43, 95% CI: 1. 17-1. 75) compared to those who did not receive chemotherapy. The likelihood of having a thromboembolic outcome was similar whether platinum chemotherapy was cisplatin- (21. 1%, AHR=1. 56, 95% CI: 1. 22-2. 00) or carboplatin-based (18. 9%, AHR=1. 35, 95% CI: 1. 07-1. 71). During years 2-5 after diagnosis there was no significant association between platinum chemotherapy and the risk of thromboembolic events. The risk of non-thromboembolic vascular events was not elevated with platinum chemotherapy in either time period.

    Patients receiving platinum based chemotherapy were at higher risk of developing thromboembolism, but not other vascular events, particularly within the first year after diagnosis. This risk of thromboembolism is similar for both cisplatin and carboplatin.

    The Journal of urology. 2015 Sep 01 [Epub ahead of print]

    Amit Gupta, Jessica B Long, Jersey Chen, Cary P Gross, Darren R Feldman, Richard M Steingart

    Department of Urology, University of Iowa, Iowa City, Iowa. Section of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Comprehensive Cancer Center and Yale School of Medicine, New Haven, Connecticut. , Kaiser Permanente, Mid-Atlantic Permanente Research Institute, Rockville, Maryland. , Section of General Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale Comprehensive Cancer Center and Yale School of Medicine, New Haven, Connecticut. , Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York. , Cardiology Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

    PubMed

    Published September 17, 2015